AG真人官方

STOCK TITAN
  1. Home
  2. Sec-filings
  3. KZR
  4. [Form 4] Kezar Life Sciences, Inc. Insider Trading Activity

[Form 4] Kezar Life Sciences, Inc. Insider Trading Activity

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Director Graham K. Cooper of Kezar Life Sciences received a stock option grant on June 18, 2025, as reported in this Form 4 filing. The transaction details include:

  • Granted 5,000 stock options to purchase common stock
  • Exercise price set at $4.46 per share
  • Options will vest 100% on June 18, 2026, subject to continued service
  • Options expire on June 17, 2035

This grant represents standard director compensation and was filed within the required reporting timeframe. The options provide Cooper with the right to purchase Kezar shares at a fixed price over the next decade, aligning his interests with shareholders' long-term value creation.

Il direttore Graham K. Cooper di Kezar Life Sciences ha ricevuto una concessione di stock option il 18 giugno 2025, come riportato in questo modulo 4. I dettagli della transazione includono:

  • Concessione di 5.000 stock option per acquistare azioni ordinarie
  • Prezzo di esercizio fissato a $4,46 per azione
  • Le opzioni matureranno al 100% il 18 giugno 2026, subordinatamente alla continuazione del servizio
  • Le opzioni scadono il 17 giugno 2035

Questa concessione rappresenta una compensazione standard per i direttori ed 猫 stata presentata entro i termini di segnalazione richiesti. Le opzioni offrono a Cooper il diritto di acquistare azioni Kezar a un prezzo fisso nel corso del prossimo decennio, allineando i suoi interessi alla creazione di valore a lungo termine per gli azionisti.

El director Graham K. Cooper de Kezar Life Sciences recibi贸 una concesi贸n de opciones sobre acciones el 18 de junio de 2025, seg煤n se informa en este formulario 4. Los detalles de la transacci贸n incluyen:

  • Otorgadas 5,000 opciones sobre acciones para comprar acciones comunes
  • Precio de ejercicio establecido en $4.46 por acci贸n
  • Las opciones se consolidar谩n al 100% el 18 de junio de 2026, sujeto a la continuidad del servicio
  • Las opciones expiran el 17 de junio de 2035

Esta concesi贸n representa una compensaci贸n est谩ndar para directores y se present贸 dentro del plazo requerido para el reporte. Las opciones le brindan a Cooper el derecho de comprar acciones de Kezar a un precio fijo durante la pr贸xima d茅cada, alineando sus intereses con la creaci贸n de valor a largo plazo para los accionistas.

Kezar Life Sciences鞚� 鞚挫偓 Graham K. Cooper電� 2025雲� 6鞗� 18鞚检棎 鞀ろ啞 鞓奠厴 攵赌鞐ゼ 氚涭晿鞙茧┌, 鞚措姅 鞚� Form 4 鞝滌稖靹滌棎 氤搓碃霅橃棃鞀惦媹雼�. 瓯半灅 靹鸽秬靷暛鞚� 雼れ潓瓿� 臧欖姷雼堧嫟:

  • 氤错喌欤茧ゼ 甑Г頃� 靾� 鞛堧姅 5,000欤� 鞀ろ啞 鞓奠厴 攵赌鞐�
  • 頄夓偓臧�瓴╈潃 欤茧嫻 $4.46搿� 靹れ爼
  • 鞓奠厴鞚赌 2026雲� 6鞗� 18鞚检棎 100% 氩犾姢韺�, 歆�靻嶌爜鞚� 攴茧 臁瓣贝 頃橃棎
  • 鞓奠厴 毵岆鞚检潃 2035雲� 6鞗� 17鞚�

鞚� 攵赌鞐姅 鞚挫偓 氤挫儊鞙茧 響滌鞝侅澑 瓴冹澊氅�, 鞖旉惮霅� 氤搓碃 旮瓣皠 雮挫棎 鞝滌稖霅橃棃鞀惦媹雼�. 鞚� 鞓奠厴鞚赌 Cooper鞐愱矊 頄ロ泟 10雲勱皠 瓿犾爼 臧�瓴╈溂搿� Kezar 欤检嫕鞚� 甑Г頃� 甓岆Μ毳� 攵赌鞐晿鞐�, 欤检＜霌れ潣 鞛リ赴鞝侅澑 臧�旃� 彀届稖瓿� 攴胳潣 鞚错暣甏�瓿勲ゼ 鞚检箻鞁滍偟雼堧嫟.

Le directeur Graham K. Cooper de Kezar Life Sciences a re莽u une attribution d'options d'achat d'actions le 18 juin 2025, comme indiqu茅 dans ce d茅p么t de formulaire 4. Les d茅tails de la transaction sont les suivants :

  • Attribution de 5 000 options d'achat d'actions pour acheter des actions ordinaires
  • Prix d'exercice fix茅 脿 4,46 $ par action
  • Les options seront acquises 脿 100 % le 18 juin 2026, sous r茅serve de la poursuite du service
  • Les options expirent le 17 juin 2035

Cette attribution repr茅sente une r茅mun茅ration standard pour les administrateurs et a 茅t茅 d茅pos茅e dans les d茅lais requis. Ces options offrent 脿 Cooper le droit d'acheter des actions Kezar 脿 un prix fixe au cours de la prochaine d茅cennie, alignant ainsi ses int茅r锚ts sur la cr茅ation de valeur 脿 long terme des actionnaires.

Direktor Graham K. Cooper von Kezar Life Sciences erhielt am 18. Juni 2025 eine Zuteilung von Aktienoptionen, wie in diesem Formular 4 gemeldet. Die Details der Transaktion umfassen:

  • Gew盲hrung von 5.000 Aktienoptionen zum Kauf von Stammaktien
  • Aus眉bungspreis festgelegt auf 4,46 $ pro Aktie
  • Optionen werden zu 100 % am 18. Juni 2026 unverfallbar, vorbehaltlich fortgesetzter Dienstzeit
  • Optionen verfallen am 17. Juni 2035

Diese Zuteilung stellt eine 眉bliche Verg眉tung f眉r Direktoren dar und wurde fristgerecht gemeldet. Die Optionen geben Cooper das Recht, Kezar-Aktien 眉ber das n盲chste Jahrzehnt zu einem festen Preis zu erwerben, wodurch seine Interessen mit der langfristigen Wertsch枚pfung der Aktion盲re in Einklang gebracht werden.

Positive
  • None.
Negative
  • None.

Il direttore Graham K. Cooper di Kezar Life Sciences ha ricevuto una concessione di stock option il 18 giugno 2025, come riportato in questo modulo 4. I dettagli della transazione includono:

  • Concessione di 5.000 stock option per acquistare azioni ordinarie
  • Prezzo di esercizio fissato a $4,46 per azione
  • Le opzioni matureranno al 100% il 18 giugno 2026, subordinatamente alla continuazione del servizio
  • Le opzioni scadono il 17 giugno 2035

Questa concessione rappresenta una compensazione standard per i direttori ed 猫 stata presentata entro i termini di segnalazione richiesti. Le opzioni offrono a Cooper il diritto di acquistare azioni Kezar a un prezzo fisso nel corso del prossimo decennio, allineando i suoi interessi alla creazione di valore a lungo termine per gli azionisti.

El director Graham K. Cooper de Kezar Life Sciences recibi贸 una concesi贸n de opciones sobre acciones el 18 de junio de 2025, seg煤n se informa en este formulario 4. Los detalles de la transacci贸n incluyen:

  • Otorgadas 5,000 opciones sobre acciones para comprar acciones comunes
  • Precio de ejercicio establecido en $4.46 por acci贸n
  • Las opciones se consolidar谩n al 100% el 18 de junio de 2026, sujeto a la continuidad del servicio
  • Las opciones expiran el 17 de junio de 2035

Esta concesi贸n representa una compensaci贸n est谩ndar para directores y se present贸 dentro del plazo requerido para el reporte. Las opciones le brindan a Cooper el derecho de comprar acciones de Kezar a un precio fijo durante la pr贸xima d茅cada, alineando sus intereses con la creaci贸n de valor a largo plazo para los accionistas.

Kezar Life Sciences鞚� 鞚挫偓 Graham K. Cooper電� 2025雲� 6鞗� 18鞚检棎 鞀ろ啞 鞓奠厴 攵赌鞐ゼ 氚涭晿鞙茧┌, 鞚措姅 鞚� Form 4 鞝滌稖靹滌棎 氤搓碃霅橃棃鞀惦媹雼�. 瓯半灅 靹鸽秬靷暛鞚� 雼れ潓瓿� 臧欖姷雼堧嫟:

  • 氤错喌欤茧ゼ 甑Г頃� 靾� 鞛堧姅 5,000欤� 鞀ろ啞 鞓奠厴 攵赌鞐�
  • 頄夓偓臧�瓴╈潃 欤茧嫻 $4.46搿� 靹れ爼
  • 鞓奠厴鞚赌 2026雲� 6鞗� 18鞚检棎 100% 氩犾姢韺�, 歆�靻嶌爜鞚� 攴茧 臁瓣贝 頃橃棎
  • 鞓奠厴 毵岆鞚检潃 2035雲� 6鞗� 17鞚�

鞚� 攵赌鞐姅 鞚挫偓 氤挫儊鞙茧 響滌鞝侅澑 瓴冹澊氅�, 鞖旉惮霅� 氤搓碃 旮瓣皠 雮挫棎 鞝滌稖霅橃棃鞀惦媹雼�. 鞚� 鞓奠厴鞚赌 Cooper鞐愱矊 頄ロ泟 10雲勱皠 瓿犾爼 臧�瓴╈溂搿� Kezar 欤检嫕鞚� 甑Г頃� 甓岆Μ毳� 攵赌鞐晿鞐�, 欤检＜霌れ潣 鞛リ赴鞝侅澑 臧�旃� 彀届稖瓿� 攴胳潣 鞚错暣甏�瓿勲ゼ 鞚检箻鞁滍偟雼堧嫟.

Le directeur Graham K. Cooper de Kezar Life Sciences a re莽u une attribution d'options d'achat d'actions le 18 juin 2025, comme indiqu茅 dans ce d茅p么t de formulaire 4. Les d茅tails de la transaction sont les suivants :

  • Attribution de 5 000 options d'achat d'actions pour acheter des actions ordinaires
  • Prix d'exercice fix茅 脿 4,46 $ par action
  • Les options seront acquises 脿 100 % le 18 juin 2026, sous r茅serve de la poursuite du service
  • Les options expirent le 17 juin 2035

Cette attribution repr茅sente une r茅mun茅ration standard pour les administrateurs et a 茅t茅 d茅pos茅e dans les d茅lais requis. Ces options offrent 脿 Cooper le droit d'acheter des actions Kezar 脿 un prix fixe au cours de la prochaine d茅cennie, alignant ainsi ses int茅r锚ts sur la cr茅ation de valeur 脿 long terme des actionnaires.

Direktor Graham K. Cooper von Kezar Life Sciences erhielt am 18. Juni 2025 eine Zuteilung von Aktienoptionen, wie in diesem Formular 4 gemeldet. Die Details der Transaktion umfassen:

  • Gew盲hrung von 5.000 Aktienoptionen zum Kauf von Stammaktien
  • Aus眉bungspreis festgelegt auf 4,46 $ pro Aktie
  • Optionen werden zu 100 % am 18. Juni 2026 unverfallbar, vorbehaltlich fortgesetzter Dienstzeit
  • Optionen verfallen am 17. Juni 2035

Diese Zuteilung stellt eine 眉bliche Verg眉tung f眉r Direktoren dar und wurde fristgerecht gemeldet. Die Optionen geben Cooper das Recht, Kezar-Aktien 眉ber das n盲chste Jahrzehnt zu einem festen Preis zu erwerben, wodurch seine Interessen mit der langfristigen Wertsch枚pfung der Aktion盲re in Einklang gebracht werden.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
COOPER GRAHAM K
(Last) (First) (Middle)
C/O KEZAR LIFE SCIENCES, INC.
4000 SHORELINE COURT, SUITE 300
(Street)
SOUTH SAN FRANCISCO CA 94080
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Kezar Life Sciences, Inc. [ KZR ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
06/18/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (right to buy) $4.46 06/18/2025 A 5,000 (1) 06/17/2035 Common Stock 5,000 $0 5,000 D
Explanation of Responses:
1. One-hundred percent (100%) of the shares subject to the option shall vest on 6/18/2026, subject to Reporting Person continuing to provide service through such date.
/s/ Marc Belsky, Attorney-in-Fact 06/23/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source:

FAQ

What stock options did KZR director Graham Cooper receive in June 2025?

Graham Cooper received a stock option grant for 5,000 shares of KZR common stock on June 18, 2025, with an exercise price of $4.46 per share. The options will fully vest on June 18, 2026, and expire on June 17, 2035.

When do Graham Cooper's KZR stock options vest?

The stock options granted to Graham Cooper will vest 100% on June 18, 2026, subject to his continued service with Kezar Life Sciences through that date.

What is the exercise price of KZR's June 2025 director stock option grant?

The stock options were granted with an exercise price of $4.46 per share.

Who filed Form 4 for KZR on June 28, 2025?

The Form 4 was filed for Graham K. Cooper, who serves as a Director of Kezar Life Sciences (KZR). The form was signed by Marc Belsky as Attorney-in-Fact on June 23, 2025.

What is the expiration date for KZR's June 2025 director stock options?

The stock options granted to Director Graham Cooper will expire on June 17, 2035, ten years after the grant date.
Stock KZR logo
Kezar Life Sciences

NASDAQ:KZR

KZR Rankings

#5547 Ranked by Market Cap
N/A Ranked by Dividends

KZR Latest News

Aug 13, 2025
Kezar Life Sciences Reports Second Quarter 2025 Financial Results and Provides Business Update
Jul 15, 2025
Kezar Life Sciences Announces FDA Has Lifted Partial Clinical Hold on PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis
May 28, 2025
Kezar Life Sciences to Participate in the Jefferies Global Healthcare Conference
May 13, 2025
Kezar Life Sciences Reports First Quarter 2025 Financial Results and Provides Business Update
Mar 25, 2025
Kezar Life Sciences Announces Positive Topline Results from the PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis (AIH) and Reports Fourth Quarter and Year End 2024 Financial Results

KZR Latest SEC Filings

Aug 13, 2025
[10-Q] Kezar Life Sciences, Inc. Quarterly Earnings Report
Aug 13, 2025
[8-K] Kezar Life Sciences, Inc. Reports Material Event
Jul 3, 2025
[Form 4] Kezar Life Sciences, Inc. Insider Trading Activity
Jul 3, 2025
[Form 4] Kezar Life Sciences, Inc. Insider Trading Activity
Jul 1, 2025
[Form 4] Kezar Life Sciences, Inc. Insider Trading Activity

KZR Stock Data

28.64M
6.34M
10.6%
58.93%
5.09%
Biotechnology
Pharmaceutical Preparations
United States
SOUTH SAN FRANCISCO